Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with evidence of vascular disease are at increased risk for subsequent vascular events despite effective use of statins to lower the low-density lipoprotein (LDL) cholesterol level. Niacin lowers the LDL cholesterol level and raises the high-density lipoprotein (HDL) cholesterol level, but its clinical efficacy and safety are uncertain. METHODS: After a prerandomization run-in phase to standardize the background statin-based LDL cholesterol-lowering therapy and to establish participants' ability to take extended-release niacin without clinically significant adverse effects, we randomly assigned 25,673 adults with vascular disease to receive 2 g of extended-release niacin and 40 mg of laropiprant or a matching placebo daily. The primary outcome was the first major vascular event (nonfatal myocardial infarction, death from coronary causes, stroke, or arterial revascularization). RESULTS: During a median follow-up period of 3.9 years, participants who were assigned to extended-release niacin-laropiprant had an LDL cholesterol level that was an average of 10 mg per deciliter (0.25 mmol per liter as measured in the central laboratory) lower and an HDL cholesterol level that was an average of 6 mg per deciliter (0.16 mmol per liter) higher than the levels in those assigned to placebo. Assignment to niacin-laropiprant, as compared with assignment to placebo, had no significant effect on the incidence of major vascular events (13.2% and 13.7% of participants with an event, respectively; rate ratio, 0.96; 95% confidence interval [CI], 0.90 to 1.03; P=0.29). Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious (absolute excess as compared with placebo, 3.7 percentage points; P<0.001) and with an increased incidence of diabetes diagnoses (absolute excess, 1.3 percentage points; P<0.001), as well as increases in serious adverse events associated with the gastrointestinal system (absolute excess, 1.0 percentage point; P<0.001), musculoskeletal system (absolute excess, 0.7 percentage points; P<0.001), skin (absolute excess, 0.3 percentage points; P=0.003), and unexpectedly, infection (absolute excess, 1.4 percentage points; P<0.001) and bleeding (absolute excess, 0.7 percentage points; P<0.001). CONCLUSIONS: Among participants with atherosclerotic vascular disease, the addition of extended-release niacin-laropiprant to statin-based LDL cholesterol-lowering therapy did not significantly reduce the risk of major vascular events but did increase the risk of serious adverse events. (Funded by Merck and others; HPS2-THRIVE ClinicalTrials.gov number, NCT00461630.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the EU, treatment with niacin was stopped after the AIM-HIGH and HPS2-THRIVE trials showed no improvement in MACE and an increased occurrence of undesirable side effects [123, 124].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [124]
In the citing paper
“Nonetheless, these studies also did not prospectively enroll patients with elevated TG levels despite statin therapy,6, 12, 13, 14, 15”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“Prior CV outcome studies that administered therapies with TG‐lowering effects (niacin or fenofibrate) on top of statin therapy did not reach their primary endpoints.”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“and an increased incidence of new-onset diabetes (absolute excess, 1.3 percentage points; P < 0.001) and disturbances in diabetes management among those with diabetes in the HPS2-THRIVE trial in those on combination therapy (161).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
In the citing paper
“Large clinical trials, including the Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trials, failed to demonstrate a benefit of adding niacin to individuals on appropriate statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Prostaglandins and Inflammation
Ricciotti, E., & FitzGerald, G. A. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207449 · Cited by 3,803
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Clofibrate and Niacin in Coronary Heart Disease
(1975) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1975.03240160024021 · Cited by 1,747
Cited by
Items 501–600 of 1,676
Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism
Ellis, K. L., Hooper, A. J., Burnett, J. R., & Watts, G. F. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.69 · Cited by 34
Is Lp(a) ready for prime time use in the clinic? A pros-and-cons debate
Kostner, K., Kostner, G. M., & Wierzbicki, A. S. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.04.032 · Cited by 36
Shen, Y. H., Chen, S., Dai, Y., Wang, X. Q., Zhang, R., YANG, Z. K., Hu, J., Lu, L., Ding, F. H., & Shen, W. F. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0888-z · Cited by 38
High-Density Lipoprotein Subspecies in Health and Human Disease: Focus on Type 2 Diabetes
Davidson, W. S., & SHAH, A. S. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-1-55 · Cited by 33
Qie, R., Liu, L., Zhang, D., Han, M., Wang, B., Zhao, Y., Liu, D., Guo, C., Li, Q., Zhou, Q., et al. (2021) · Preventing Chronic Disease · doi:10.5888/pcd18.200278 · Cited by 39
Lipoprotein (a): When to Measure and How to Treat?
Rhainds, D., Brodeur, M. R., & Tardif, J. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00951-2 · Cited by 35
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future
Kalaycı, A., Gibson, C. M., Ridker, P. M., Wright, S. D., Kingwell, B. A., Korjian, S., Chi, G., Lee, J., Tricoci, P., Kazmi, S. H. A., et al. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01025-7 · Cited by 38
Omega-3-fatty acids: Do they prevent cardiovascular disease?
Mason, R. P., Sherratt, S. C. R., & Eckel, R. H. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101681 · Cited by 44
Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans
Doi, T., Langsted, A., & Nordestgaard, B. G. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22013 · Cited by 40
Relation between plasma and brain lipids
Wellington, C. L., & Frikke-Schmidt, R. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000291 · Cited by 33
Differentiating EPA from EPA/DHA in cardiovascular risk reduction
Toth, P. P., Chapman, M. J., Parhofer, K. G., & Nelson, J. R. (2022) · American Heart Journal Plus: Cardiology Research and Practice · doi:10.1016/j.ahjo.2022.100148 · Cited by 33
Gibson, C. M., Korjian, S., Tricoci, P., Daaboul, Y., Alexander, J. H., Steg, P. G., Lincoff, A. M., Kastelein, J. J. P., Mehran, R., D’Andrea, D. M., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.06.017 · Cited by 36
Lu, Y., Zhou, S., Dreyer, R. P., Caulfield, M. P., Spatz, E. S., Geda, M. E., Lorenze, N. P., Herbert, P. N., D’Onofrio, G., Jackson, E. A., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.09.012 · Cited by 33
Cahill, L. E., Sacks, F. M., Rimm, E. B., & Jensen, M. K. (2019) · Journal of Lipid Research · doi:10.1194/jlr.p093823 · Cited by 34
Xu, W., Li, L., & Zhang, L. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00901 · Cited by 35
Niacin Increases Atherogenic Proteins in High-Density Lipoprotein of Statin-Treated Subjects
Ronsein, G. E., Vaisar, T., Davidson, W. S., Bornfeldt, K., Probstfield, J. L., O’Brien, K. D., Zhao, X.-Q., & Heinecke, J. W. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316278 · Cited by 35
Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects
Mijares, A. H., Ascaso, J. F., Blasco, M., Brea, Á., Díaz, Á., Mantilla, T., Pedro‐Botet, J., Pintó, X., & Millán, J. (2019) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2019.02.002 · Cited by 37
Ying, H., Gao, L., Liao, N., Xu, X., Yu, W., & Hong, W. (2022) · BMC Cancer · doi:10.1186/s12885-022-10265-4 · Cited by 35
NAD + Precursors in Human Health and Disease: Current Status and Future Prospects
Yaku, K., & Nakagawa, T. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0354 · Cited by 33
“However, the combination of NA and statin failed to reduce the risk of major vascular events and increased the risk of serious adverse events (Boden et al., 2011; Landray et al., 2014; Ronsein et al., 2021).”
Xie, S., Galimberti, F., Olmastroni, E., Carugo, S., Catapano, A. L., & Casula, M. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120420 · Cited by 43
Savinova, O. V., Fillaus, K., Harris, W. S., & Shearer, G. C. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.04.793 · Cited by 33
Low High-Density Lipoprotein and Risk of Myocardial Infarction
Ramirez, A., & Hu, P. P. (2015) · Clinical Medicine Insights Cardiology · doi:10.4137/cmc.s26624 · Cited by 37
Does Supplementation with Omega-3 PUFAs Add to the Prevention of Cardiovascular Disease?
Rizos, E. C., & Elisaf, M. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0856-8 · Cited by 31
Drug Therapy of Dyslipidemia in the Elderly
Yandrapalli, S., Gupta, S., Andries, G., Cooper, H. A., & Aronow, W. S. (2019) · Drugs & Aging · doi:10.1007/s40266-018-00632-x · Cited by 32
Adorni, M. P., Zimetti, F., Cangiano, B., Vezzoli, V., Bernini, F., Caruso, D., Corsini, A., Sirtori, C. R., Cariboni, A. M., Bonomi, M., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02027 · Cited by 33
Jonas, K., & Kopeć, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143514 · Cited by 33
“of increasing HDL concentration with nicotinic acid [12], current trials with extended-release niacin as an add-on therapy to the background statin failed to reduce the risk of cardiovascular events [13,14].”
BackgroundCardiovascular effects of omega-3 fatty acids: Hope or hype?
Jo, S., Han, S. H., Kim, S., Eckel, R. H., & Koh, K. K. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.02.014 · Cited by 34
Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies
Handhle, A., Viljoen, A., & Wierzbicki, A. S. (2021) · Vascular Health and Risk Management · doi:10.2147/vhrm.s266244 · Cited by 33
HDL maturation and remodelling
Ong, K. L., Cochran, B. J., Manandhar, B., Thomas, S. R., & Rye, K. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159119 · Cited by 39
Benefits of Streamlined Point-of-Care Trial Designs
Califf, R. M., Cavazzoni, P. A., & Woodcock, J. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.4810 · Cited by 31
Targeting Gastrointestinal Transport Proteins to Control Hyperphosphatemia in Chronic Kidney Disease
Fouque, D. P., Vervloet, M. G., & Ketteler, M. (2018) · Drugs · doi:10.1007/s40265-018-0950-2 · Cited by 32
“The ERN formulation in combination with laropiprant and/or statins (HMGCoA reductase inhibitors) has been assessed in several clinical studies in patients with cardiovascular disease [98, 99].”
BackgroundCETP: Pharmacogenomics-Based Response to the CETP Inhibitor Dalcetrapib
Tardif, J., Rhainds, D., Rhéaume, É., & Dubé, M. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307122 · Cited by 35
Low levels of small HDL particles predict but do not influence risk of sepsis
Hamilton, F., Pedersen, K. M., Ghazal, P., Nordestgaard, B. G., & Smith, G. D. (2023) · Critical Care · doi:10.1186/s13054-023-04589-1 · Cited by 32
“Thirdly, a single placebo-controlled randomised trial of extended release niacin unexpectedly showed an increase in infection in those assigned to niacin, which was also shown to increase HDL cholesterol [15].”
BackgroundLipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?
Tsioulos, G., Kounatidis, D. C., Vallianou, N. G., Poulaki, A., Kotsi, E., Christodoulatos, G. S., Tsilingiris, D., Karampela, Ι., Skourtis, A., & Dalamaga, Μ. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063537 · Cited by 40
“Furthermore, the use of niacin has been linked to clinically significant adverse events, including newly diagnosed or worsened diabetes mellitus, gastrointestinal issues, musculoskeletal problems, skin manifestations, and an increased incidence of infections and bleeding [180].”
BackgroundFeingold, K. R., & Grünfeld, C. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_14 · Cited by 50
Padala, S. K., Sidhu, M. S., & Boden, W. E. (2016) · Springer eBooks · doi:10.1007/978-3-642-37393-0_70-2 · Cited by 30
Plaque imaging to refine indications for emerging lipid-lowering drugs
Alkhalil, M., Chai, J. T., & Choudhury, R. P. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw034 · Cited by 33
“Protection Study 2—Treatment of HDL to Reduce the Incidence of Vascular Events), NA was again shown not to confer any additional benefit in reduction in major vascular events in optimally statintreated patient.(61) In fact, there was a non-significant 9% proportional 60 M.”
BackgroundMethodDavidson, W. S., Heink, A., Sexmith, H., Dolan, L. M., Gordon, S. M., Otvos, J. D., Melchior, J. T., Elder, D. A., Khoury, J., Geh, E., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m078667 · Cited by 30
Treatment of Cholesterol in 2017
Krumholz, H. M. (2017) · JAMA · doi:10.1001/jama.2017.6753 · Cited by 30
Gonna, H., & Ray, K. K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13691 · Cited by 33
“64 mmol/L.(116) The increase in HDL-C was 17% and the reduction in LDL-C with nicotinic acid was 20% but given the low starting baseline level of LDL-C the absolute reduction in LDL-C was modest which in part may explain the modest non-significant difference in outcomes (HR 0.”
BackgroundHaynes, R., Valdés‐Márquez, E., Hopewell, J. C., Chen, F., Li, J., Parish, S., Landray, M., Armitage, J., Haynes, R., Valdés‐Márquez, E., et al. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.06.012 · Cited by 31
Targeting hypertriglyceridemia to mitigate cardiovascular risk: A review
Toth, P. P., Shah, P. K., & Lepor, N. E. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100086 · Cited by 37
Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition
Musunuru, K. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-080819-044918 · Cited by 34
Development and Validation of a Predictive Model for Coronary Artery Disease Using Machine Learning
Wang, C., Zhao, Y., Jin, B., Gan, X., Liang, B., Xiang, Y., Zhang, X., Lu, Z., & Zheng, F. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.614204 · Cited by 38
A new phenotypic classification system for dyslipidemias based on the standard lipid panel
Sampson, M. L., Ballout, R. A., Soffer, D. E., Wolska, A. T., Wilson, S. R., Meeusen, J. W., Donato, L. J., Fatica, E. M., Otvos, J. D., Brinton, E. A., et al. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01585-8 · Cited by 37
“Fibrates or nicotinic acid could also be considered [50], but ASCVD benefit has not yet been demonstrated for these drugs in randomized clinical trials when used with statins [14, 33, 50, 59, 60].”
BackgroundDeora, N., & Venkatraman, K. (2022) · Journal of Ayurveda and Integrative Medicine · doi:10.1016/j.jaim.2022.100675 · Cited by 48
Defining the Place of Ezetimibe/Atorvastatin in the Management of Hyperlipidemia
Ferreira, A. M., & da Silva, P. M. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0205-0 · Cited by 35
Batuca, J., Amaral, M., Favas, C., Paula, F., Ames, P., Papoila, A., & Alves, J. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13198 · Cited by 27
Rediscovering scavenger receptor type BI: surprising new roles for the HDL receptor
Hoekstra, M., & Sorci‐Thomas, M. G. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000413 · Cited by 30
Causal Effect of Lipids and Lipoproteins on Atherosclerosis
Ference, B. A. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.001 · Cited by 28
High‐density lipoprotein in diabetes: Structural and functional relevance
Lui, D. T. W., & Tan, K. C. B. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14172 · Cited by 37
“Unfortunately, the results were disappointing when randomized controlled trials with niacin 11 and CETP inhibitors 12 did not show a reduction in cardiovascular events, despite signi fi cantly increasing HDL-C levels.”
Zein, M. A., Khazzeka, A., Khoury, A. E., Zein, J. A., Dima, Z., & Eid, A. H. (2024) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.10.009 · Cited by 37
Yadav, R., Liu, Y., Kwok, S., Hama, S., France, M. W., Eatough, R., Pemberton, P., Schofield, J. D., Siahmansur, T. J., Malik, R. A., et al. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001508 · Cited by 29
Pharmacological management of diabetic dyslipidemia
Filippatos, T. D., Florentin, M., Georgoula, M., & Elisaf, M. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1263565 · Cited by 33
Li, Y., & Rosenblit, P. D. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1051-2 · Cited by 31
Genetic control of the mouse HDL proteome defines HDL traits, function, and heterogeneity
Pamir, N., Pan, C., Plubell, D. L., Hutchins, P. M., Tang, C., Wimberger, J., Irwin, A. D., Vallim, T. Q. D. A., Heinecke, J. W., & Lusis, A. J. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m090555 · Cited by 30
“However, pharmacological interventions aimed at raising HDL-C levels in humans showed no cardiovascular benefits (72) (73) (74) (75) .”
BackgroundThambiah, S. C., & Lai, L. C. (2021) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2021.e00248 · Cited by 51
Safety of Statins and Nonstatins for Treatment of Dyslipidemia
Newman, C. B. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.01.004 · Cited by 39
Naerr, G. W., Rein, P., Saely, C. H., & Drexel, H. (2016) · Vascular Pharmacology · doi:10.1016/j.vph.2016.01.006 · Cited by 30
Complications of Diabetes Mellitus
Brownlee, M., Aiello, L. P., Cooper, M. E., Vinik, A. I., Plutzky, J., & Boulton, A. J. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00033-2 · Cited by 43
Abdel‐Razek, O., Sadananda, S. N., Li, X., Cermakova, L., Frohlich, J. J., & Brunham, L. R. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.10.010 · Cited by 29
Sea Change for Marine Omega-3s
O'Keefe, E. L., Harris, W. S., DiNicolantonio, J. J., Elagizi, A., Milani, R. V., Lavie, C. J., & O'Keefe, J. H. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.04.027 · Cited by 28
HDL abnormalities in type 2 diabetes: Clinical implications
Martagón, A. J., Zubirán, R., González-Arellanes, R., Praget-Bracamontes, S., Rivera-Alcántara, J. A., & Aguilar-Salinas, C. A. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117213 · Cited by 34
Jones, J. E., Tang, K. S., Barseghian, A., & Wong, N. D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12237432 · Cited by 36
Role of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease in South Asian Individuals
Patel, D., Koschinsky, M. L., Agarwala, A., Natarajan, P., Bhatia, H. S., Mehta, A., Patel, J., Peters, M. G., Pandya, S., Sagheer, U., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.040361 · Cited by 35
Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future
Stein, E. A., & Raal, F. J. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0659-8 · Cited by 29
Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes
Turner, T. A., & Stein, E. A. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.09.004 · Cited by 31
Borja, M. S., Hammerson, B., Tang, C., Savinova, O. V., Shearer, G. C., & Oda, M. N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182217 · Cited by 31
Hypertriglyceridemia in Diabetes Mellitus: Implications for Pediatric Care
Hartz, J. C., de Ferranti, S. D., & Gidding, S. S. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00079 · Cited by 32
Familial hypercholesterolemia: Detect, treat, and ask about family
Shah, N. P., Ahmed, H. M., & Tang, W. H. W. (2020) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.87a.19021 · Cited by 32
“53,54 Fibrates are typically used to lower triglyceride levels.”
BackgroundAtherosclerosis Regression and Cholesterol Efflux in Hypertriglyceridemic Mice
Josefs, T., Basu, D., Vaisar, T., Arets, B., Kanter, J. E., Huggins, L.-A., Hu, Y., Liu, J., Clouet-Foraison, N., Heinecke, J. W., et al. (2021) · Circulation Research · doi:10.1161/circresaha.120.317458 · Cited by 28
Changing Perspectives on HDL: From Simple Quantity Measurements to Functional Quality Assessment
Thakkar, H., Vincent, V., Sen, A., Singh, A., & Roy, A. (2021) · Journal of Lipids · doi:10.1155/2021/5585521 · Cited by 35
A VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in mice
Fowler, A., Sampson, M. L., Remaley, A. T., & Chackerian, B. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.077 · Cited by 29
Mendelian randomization: Its impact on cardiovascular disease
Kawashiri, M., Tada, H., Nomura, A., & Yamagishi, M. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2018.04.007 · Cited by 29
Wu, N., Guo, Y., Zhu, C., Gao, Y., Zhao, X., Sun, D., Sun, J., Xu, R., Liu, G., Dong, Q., et al. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0909-z · Cited by 32
“Introduction According to the 2013 American Cardiology College/ American Heart Association (ACC/AHA) guideline of cholesterol management, the patients at very high risk of atherosclerotic cardiovascular diseases (ASCVD) should take high intensity statins whatever the low-density lipoprotein cholesterol (LDL-C) level w…”
MethodFanaroff, A. C., Clare, R. M., Pieper, K. S., Mahaffey, K. W., Melloni, C., Green, J. B., Alexander, J. H., Jones, W. S., Harrison, R. W., Mehta, R. H., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037202 · Cited by 31
Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?
Nelson, J. R., True, W. S., Le, V., & Mason, R. P. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1385365 · Cited by 27
Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review
Zimodro, J. M., Rizzo, M., & Gouni‐Berthold, I. (2025) · Pharmaceuticals · doi:10.3390/ph18020147 · Cited by 32
Feingold, K. R. (2015) · Europe PMC (PubMed Central) · Cited by 36
Poller, W. C., Berger, A., Dreger, H., Morgera, S., & Enke-Melzer, K. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.007 · Cited by 27
Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus
Kosmas, C. E., Silverio, D., Sourlas, A., Garcia, F., Montan, P. D., & Guzman, E. (2018) · Drugs in Context · doi:10.7573/dic.212562 · Cited by 36
Menon, V., Kumar, A., Patel, D. R., John, J. S., Riesmeyer, J., Weerakkody, G. J., Ruotolo, G., Wolski, K., McErlean, E. S., Cremer, P. C., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000943 · Cited by 32
Hyperalphalipoproteinemia and Beyond: The Role of HDL in Cardiovascular Diseases
Giammanco, A., Noto, D., Barbagallo, C. M., Nardi, E., Caldarella, R., Ciaccio, M., Averna, M. R., & Cefalu, A. B. (2021) · Life · doi:10.3390/life11060581 · Cited by 31
Elevated lipoprotein (a) levels and risk of peripheral artery disease outcomes: A systematic review
Masson, W. M., Lobo, M., Barbagelata, L., Molinero, G., Bluro, I. M., & Nogueira, J. P. (2022) · Vascular Medicine · doi:10.1177/1358863x221091320 · Cited by 31
Effects of Lipid-Modifying and Other Drugs on Lipoprotein(a) Levels—Potent Clinical Implications
Koutsogianni, A. D., Liamis, G. L., Liberopoulos, E. N., Adamidis, P. S., & Florentin, M. (2023) · Pharmaceuticals · doi:10.3390/ph16050750 · Cited by 35
“Importantly, studies with cardiovascular outcomes showed no benefit of adding niacin to statins [40,41].”
BackgroundMani, P., Ren, H.-Y., Neeland, I. J., McGuire, D. K., Ayers, C. R., Khera, A., & Rohatgi, A. K. (2016) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2016.12.028 · Cited by 30
NAD+ and Vascular Dysfunction: From Mechanisms to Therapeutic Opportunities
Abdellatif, M., Bugger, H., Kroemer, G., & Sedej, S. (2022) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2022.11.2.111 · Cited by 35
Lipoprotein(a): Cardiovascular Disease, Aortic Stenosis and New Therapeutic Option
Maloberti, A., Fabbri, S., Colombo, V., Gualini, E., Monticelli, M., Daus, F., Busti, A., Galasso, M., Censi, L. D., Algeri, M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010170 · Cited by 32
Sprecher, D. L., Maxwell, M. P., Goodman, J., White, B. P., Tang, C.-M., Boullay, V., & de Gouville, A. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.01.051 · Cited by 26
“Other possible mechanisms of action may involve an inhibitory effect on cholesteryl ester transfer protein (Offermanns, 2006; Gille et al., 2008), or selective reduction in hepatic clearance of HDL apolipoprotein-A1 containing particles (Jin et al., 1997).”
BackgroundCardioprotective Properties of HDL: Structural and Functional Considerations
Pappa, E. T., Elisaf, M., Kostara, C. E., Bairaktari, E. T., & Tsimihodimos, V. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190201142321 · Cited by 30
What Causes Premature Coronary Artery Disease?
Le, A., Peng, H., Golinsky, D., Scipio, M. D., Lali, R., & Paré, G. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01200-y · Cited by 38
New Cholesterol Guidelines for the Management of Atherosclerotic Cardiovascular Disease Risk
Adhyaru, B. B., & Jacobson, T. A. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.09.002 · Cited by 31
Klančič, T., Woodward, L., Hofmann, S. M., & Fisher, E. A. A. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.03.001 · Cited by 34
“CONFLICT OF INTEREST None declared.”
Fatty acids and the risk of death during acute myocardial ischaemia
Oliver, M. F. (2014) · Clinical Science · doi:10.1042/cs20140404 · Cited by 32
Gulizia, M. M., Colivicchi, F., Ricciardi, G., Giampaoli, S., Maggioni, A. P., Averna, M. R., Graziani, M. S., Ceriotti, F., Mugelli, A., Rossi, F., et al. (2017) · European Heart Journal Supplements · doi:10.1093/eurheartj/sux029 · Cited by 27
PCSK9 as a therapeutic target for cardiovascular disease
Zhang, P.-Y. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4055 · Cited by 31
Improving public health by improving clinical trial guidelines and their application
Landray, M., Bax, J. J., Alliot, L., Buyse, M. E., Cohen, A. F., Collins, R., Hindricks, G., James, S. K., Lane, S., Maggioni, A. P., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx086 · Cited by 26
“However, it also carries risks (for example, data-derived subgroup analyses may yield unreliable conclusions and lead to inappropriate treatment decisions) and opportunity costs (diverting resources away from new trials of cardiovascular treatments), so moves in this direction should be considered carefully.(61,62)”
BackgroundLipid-lowering treatment in peripheral artery disease
Katsiki, N., Giannoukas, A. D., Athyros, V. G., & Mikhailidis, D. P. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.01.003 · Cited by 27
“HPS2-THRIVE Collaborative Group: Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R et al.: Effects of extended-release niacin with laropiprant in high-risk patients.”
White, C. M. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015608487 · Cited by 26
Akivis, Y., Alkaissi, H. R., McFarlane, S. I., & Bukharovich, I. F. (2024) · Current Cardiology Reviews · doi:10.2174/011573403x272750240109052319 · Cited by 34
Metadata
- Authors
- The HPS2-THRIVE Collaborative Group
- Corresponding author
- The HPS2-THRIVE Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-17
- Volume
- 371
- Issue
- 3
- Pages
- 203-212
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1856460279
- Cited by
- 1,668
- References
- 33
- Citations by year
- 2026: 72 · 2025: 73 · 2024: 107 · 2023: 113 · 2022: 115 · 2021: 119 · 2020: 132 · 2019: 144 · 2018: 149 · 2017: 159 · 2016: 203 · 2015: 204 · 2014: 71
- FWCI
- 210.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion, other-oa)
- Funders
- Harbin Medical University
- Second Affiliated Hospital of Harbin Medical University
- Cancer Research UK
- National Institute for Health and Care Research (CDF-2013-06-012)
- British Heart Foundation (RE/08/004)
- Tongji University
- Zhengzhou University
- Qingdao University
- First Affiliated Hospital of Zhengzhou University
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- extended-release niacin, laropiprant, LDL cholesterol lowering, HDL cholesterol, major vascular events, secondary prevention, vascular disease, statin therapy, diabetes management, adverse events, cardiovascular risk reduction, lipid-lowering therapy, coronary artery disease, stroke, myocardial infarction, arterial revascularization, infection risk
- MeSH terms
- Aged, Hypolipidemic Agents, Delayed-Action Preparations, Diabetes Mellitus, Double-Blind Method, Drug Combinations, Female, Follow-Up Studies, Hemorrhage, Humans, Hypercholesterolemia, Indoles, Infections, Cholesterol, LDL, Male, Middle Aged, Musculoskeletal Diseases, Niacin, Risk Factors, Treatment Failure, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.